Clinical Impact of 11q13.3 Amplification on Immune Cell Infiltration and Prognosis in Breast Cancer
Renyu Zhou,Xiaoxi Zhu,Yulong Peng,Lijuan Zhong,Lilin Peng,Bo Yang,Yuhua Meng,Xuanzhao Chen,Yuanzhi Lu
DOI: https://doi.org/10.2147/IJGM.S360177
IF: 2.145
2022-04-14
International Journal of General Medicine
Abstract:Renyu Zhou, 1 Xiaoxi Zhu, 2 Yulong Peng, 1 Lijuan Zhong, 1 Lilin Peng, 1 Bo Yang, 1 Yuhua Meng, 3 Xuanzhao Chen, 4 Yuanzhi Lu 1, 4 1 Department of Pathology, First Affiliated Hospital of Jinan University, Guangzhou, 510630, People's Republic of China; 2 Department of Oncology, First Affiliated Hospital of Jinan University, Guangzhou, 510630, People's Republic of China; 3 Department of Pathology, Shunde Hospital, Southern Medical University (The First People's Hospital of Shunde), Foshan, 528300, People's Republic of China; 4 The Center of Pathological Diagnosis and Research, Affiliated Hospital of Guangdong Medical University, Zhanjiang, 524023, People's Republic of China Correspondence: Yuanzhi Lu, Tel +86-20 38688984, Email Introduction: Amplification of the 11q13.3 locus has been observed in various tumors. This study sought to determine the correlation of gene amplification at the 11q13.3 locus with the immune status and survival of breast cancer. Methods: Amplification of the 11q13.3 locus was characterized by analyzing a publicly available database from the cBioPortal platform (TCGA). The correlation of amplified genes with immune cell infiltration in breast cancer was further analyzed using the TIMER2.0 platform. Immunohistochemical staining was used to determine the expression levels of Cyclin D1 (CCND1), Fas-associated death domain (FADD) and P53 in 156 clinical breast cancer samples. Results: This study revealed that amplification of the 11q13.3 amplicon in breast cancer is likely more frequently detected in luminal B breast cancer. Moreover, high expression or amplification of CCND1 , fibroblast growth factor 3 ( FGF3 ), fibroblast growth factor 4 ( FGF4 ), fibroblast growth factor 19 ( FGF19 ) and FADD was inversely correlated with the abundance of CD4+ T cells and dendritic cell infiltration in breast cancer ( P < 0.05). Data analysis also demonstrated that high expression of CCND1, FGF4 and FADD mRNA levels was closely correlated with shorter recurrence-free survival (RFS) in patients with breast cancer ( P < 0.05). The results of immunohistochemical staining from clinical samples further confirmed that high expression of CCND1 and FADD was frequently detected in luminal B and high-grade breast cancer with shorter metastasis-free survival times ( P < 0.05). Conclusion: This study demonstrated that coamplification of genes located on the 11q13.3 amplicon is frequently detected in luminal B subtype breast cancer and is closely associated with worse survival in patients with breast cancer. Moreover, coamplification of the CCND1-FGF locus might decrease antitumor immune activity in breast cancer, indicating that coamplification of the 11q13.3 amplicon is likely to be a key determinant of therapeutic resistance and accelerate the aggressive evolution of breast cancer. Keywords: breast cancer, chromosomal amplification, 11q13.3 amplicon, prognosis, immune microenvironment Breast cancer (BC) is a malignant tumor with a high incidence in women worldwide, threatening women's health and lives, and it has become the "first killer" that endangers women's health. 1 Its incidence is accelerating globally and tends to be detected younger. 2–4 Early studies based on the results of mRNA profiling divided breast cancer into five intrinsic subtypes: luminal A, luminal B, HER2-enriched, basal cell-like and normal breast-like subtypes. 5 Clinically, immunohistochemical detection of ER, PR, HER2 and Ki67 can roughly distinguish the intrinsic subtypes of breast cancer and guide adjuvant therapy with anti-endocrine or targeting regimens such as chemotherapy plus tamoxifen or fulvestrant for ER+/PR+ breast cancer and trastuzumab or pertuzumab for HER2-enriched subtypes of breast cancer. However, approximately 30–40% of breast cancer patients develop primary and/or acquired drug-resistant recurrence and ultimately metastasis to bones, lungs, liver and brain. It has been demonstrated that different oncogenic driver alterations may contribute to recurrence or metastasis in different subtypes of breast cancer, highlighting that driver mutations of PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha), ESR1 (estrogen receptor 1), AKT1 (AKT serine/threonine kinase 1) and GATA3 (GATA binding protein 3) as well as inactivation of PTEN (phosphatase and tensin homolog) and NF1 (neurofibromin 1) are frequently present in metastatic hormone receptor (HR)-positive breast cancer. 6,7 Additional -Abstract Truncated-